Tolerability and efficacy of inhaled AZD4818, a CCR1 antagonist, in moderate to severe COPD patients

Respiratory Medicine

Volumn 104, Issue 9, 2010, Pages 1297-1303

  Kerstjens, Huib A ^a   Bjermer, Leif ^b   Eriksson, Leif ^c   Dahlström, Kerstin ^c   Vestbo, Jørgen ^d  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c ASTRAZENECA R AND D   (Sweden)

^d HVIDOVRE HOSPITAL   (Denmark)

Author keywords

AZD4818; Chemokine receptor antagonist; COPD; Disease modification

Indexed keywords

AZD 4818; CHEMOKINE RECEPTOR ANTAGONIST; PLACEBO; UNCLASSIFIED DRUG;

AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FORCED EXPIRATORY VOLUME; HEALTH STATUS; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SCORING SYSTEM;

AGED; BRONCHODILATOR AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DYSPNEA; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; METERED DOSE INHALERS; MIDDLE AGED; PIPERIDINES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; SPIRO COMPOUNDS; TREATMENT OUTCOME;

EID: 77955664554     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2010.04.010     Document Type: Article

References (18)

1. H. Brühl, K. Wagner, H. Kellner, M. Schattenkirchner, D. Schlöndorff, and M. Mack Surface expression of CC- and CXC-chemokine receptors on leucocyte subsets in inflammatory joint diseases Clin Exp Immunol 126 2001 551 559
2. J.E. Pease, and R. Horuk CCR1 antagonists in clinical development Expert Opin Investig Drugs 14 2005 785 796
3. T. Saeki, and A. Naya CCR1 chemokine receptor antagonist Curr Pharm Des 9 2003 1201 1218
4. T. van der Molen, B.W. Willemse, S. Schokker, N.H. ten Hacken, D.S. Postma, and E.F. Juniper Development, validity and responsiveness of the clinical COPD questionnaire Health Qual Life Outcomes 1 2003 13
5. J.A. Mo, A.H. Jansson, and E. Morin et al. Inhaled CCR1 antagonist AZD4818 reduces leucocyte influx in the rate lipopolysaccharide (LPS) lung inflammation model Eur Respir J 34 Suppl. 53 2009 559S [Abstract 3243]
6. Mo JA. Personal communication. Manuscript in preparation.
7. J.F. Cheng, and R. Jack CCR1 antagonists Mol Divers 12 2008 17 23
8. R. Horuk Chemokine receptor antagonists: overcoming developmental hurdles Nat Rev Drug Discov 8 2009 23 33
9. M. Liang, M. Rosser, and H.P. Ng et al. Species selectivity of a small molecule antagonist for the CCR1 chemokine receptor Eur J Pharmacol 389 2000 41 49
10. J.B. Domachowske, C.A. Bonville, J.L. Gao, P.M. Murphy, A.J. Easton, and H.F. Rosenberg MIP-1alpha is produced but does not control pulmonary inflammation in response to respiratory syncytial virus infection in mice Cell Immunol 206 2000 1 6
11. R.P. Gladue, S.H. Cole, and M.L. Roach et al. The human specific CCR1 antagonist CP-481,715 inhibits cell infiltration and inflammatory responses in human CCR1 transgenic mice J Immunol 176 2006 3141 3148
12. B.J. O'Connor, B. Leaker, and P. Barnes et al. Inhibition of LPS-induced inflammation in healthy volunteers Eur Respir J 30 Suppl. 2007 209S [Abstract 1294]
13. F. Zipp, H.P. Hartung, and J. Hillert et al. Blockade of chemokine signalling in patients with multiple sclerosis Neurology 67 2006 1880 1883
14. R. Horuk BX471: a CCR1 antagonist with anti-inflammatory activity in man Mini Rev Med Chem 5 2005 791 804
15. S. Ribeiro, and R. Horuk The clinical potential of chemokine receptor antagonists Pharmacol Ther 107 2005 44 58
16. R.P. Gladue, L.A. Tylaska, and W.H. Brisette et al. CP-481,715, a potent and selective CCR1 antagonist with potential therapeutic implications for inflammatory diseases J Biol Chem 278 2003 40473 40480
17. M. He, R. Horuk, and M. Bhatia Treatment with BX471, a nonpeptide CCR1 antagonist protects mice against acute pancreatitis-associated lung injury by modulating neutrophil recruitment Pancreas 34 2007 233 241
18. M. He, R. Horuk, S.M. Moochhala, and M. Bhatia Treatment with BX471, a CC chemokine receptor 1 antagonist, attenuates systemic inflammatory response during sepsis Am J Physiol Gastrointest Liver Physiol 292 2007 G1173 G1180